[go: up one dir, main page]

LT4349B - 2-metil-tieno-benzodiazepino kristalinės formos ir jų gavimo būdas - Google Patents

2-metil-tieno-benzodiazepino kristalinės formos ir jų gavimo būdas Download PDF

Info

Publication number
LT4349B
LT4349B LT97-148A LT97148A LT4349B LT 4349 B LT4349 B LT 4349B LT 97148 A LT97148 A LT 97148A LT 4349 B LT4349 B LT 4349B
Authority
LT
Lithuania
Prior art keywords
olanzapine
methyl
less
benzodiazepine
active ingredient
Prior art date
Application number
LT97-148A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT97148A (lt
Inventor
Charles Arthur Bunnell
Barry Arnold Hendriksen
Samuel Dean Larsen
Original Assignee
Eli Lilly And Company
Lilly Industries Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23621056&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT4349(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company, Lilly Industries Limited filed Critical Eli Lilly And Company
Publication of LT97148A publication Critical patent/LT97148A/xx
Publication of LT4349B publication Critical patent/LT4349B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
LT97-148A 1995-03-24 1997-09-16 2-metil-tieno-benzodiazepino kristalinės formos ir jų gavimo būdas LT4349B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40956695A 1995-03-24 1995-03-24

Publications (2)

Publication Number Publication Date
LT97148A LT97148A (lt) 1998-01-26
LT4349B true LT4349B (lt) 1998-05-25

Family

ID=23621056

Family Applications (1)

Application Number Title Priority Date Filing Date
LT97-148A LT4349B (lt) 1995-03-24 1997-09-16 2-metil-tieno-benzodiazepino kristalinės formos ir jų gavimo būdas

Country Status (48)

Country Link
US (1) US5736541A (de)
EP (3) EP0733635B1 (de)
JP (1) JPH11502535A (de)
KR (1) KR100399688B1 (de)
CN (1) CN1065536C (de)
AP (1) AP828A (de)
AR (2) AR002719A1 (de)
AT (4) ATE331719T1 (de)
AU (1) AU706471B2 (de)
BG (1) BG62619B1 (de)
BR (1) BR9607790A (de)
CA (1) CA2214005C (de)
CH (1) CH690579A5 (de)
CO (1) CO4650278A1 (de)
CZ (1) CZ292688B6 (de)
DE (4) DE69614426T2 (de)
DK (4) DK0733635T3 (de)
EA (1) EA000149B1 (de)
EE (1) EE03489B1 (de)
EG (1) EG23659A (de)
ES (3) ES2208220T3 (de)
FI (1) FI973750L (de)
GB (1) GB2313835B (de)
HU (1) HU224989B1 (de)
IL (1) IL117610A (de)
IS (1) IS1896B (de)
LT (1) LT4349B (de)
LU (1) LU90096B1 (de)
LV (1) LV12018B (de)
MY (1) MY114701A (de)
NO (1) NO314663B1 (de)
NZ (1) NZ306110A (de)
OA (1) OA10510A (de)
PA (1) PA8353701A1 (de)
PE (1) PE44897A1 (de)
PL (1) PL183723B1 (de)
PT (3) PT1095941E (de)
RO (1) RO118872B1 (de)
SE (1) SE9703205L (de)
SI (4) SI9620040B (de)
SK (1) SK284143B6 (de)
SV (1) SV1996000031A (de)
TR (1) TR199701017T1 (de)
TW (2) TW513432B (de)
UA (1) UA44765C2 (de)
WO (1) WO1996030375A1 (de)
YU (1) YU49478B (de)
ZA (2) ZA962342B (de)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
WO1997011700A1 (en) * 1995-09-29 1997-04-03 Eli Lilly And Company Method for treating a tic disorder
BR9708181A (pt) * 1996-03-11 1999-07-27 Lilly Co Eli Método parsa tratamento da insônia
UA57727C2 (uk) * 1996-03-11 2003-07-15 Елі Ліллі Енд Компані Спосіб лікування надмірної агресивності
PL329221A1 (en) * 1996-03-25 1999-03-15 Lilly Co Eli Method of relieving hemicrania pains
JP2000507546A (ja) * 1996-03-25 2000-06-20 イーライ・リリー・アンド・カンパニー 麻酔方法
NZ332039A (en) * 1996-03-25 2000-06-23 Lilly Co Eli Method for treating pain using olanzapine and NSAIDs
CZ298198A3 (cs) * 1996-03-25 1999-06-16 Eli Lilly And Company Farmaceutický přípravek
TR199900639T2 (xx) * 1996-09-23 1999-06-21 Eli Lilly And Company Olanzapin dihidrat D.
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
WO1998046596A1 (en) * 1997-04-15 1998-10-22 Eli Lilly And Company Method for providing neuro-protective effects
ZA982917B (en) * 1997-04-15 1999-10-06 Lilly Co Eli Method for treating cerebral focal stroke.
US20030022889A1 (en) * 1997-04-15 2003-01-30 Bymaster Franklin P. Method for providing neuro-protective effects
DK1155696T3 (da) * 1997-04-15 2004-07-12 Lilly Co Eli Anvendelse af olanzapin til fremstillingen af et medikament til neurobeskyttelse
USRE43932E1 (en) 1997-07-18 2013-01-15 Novartis Ag Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use
US6617321B2 (en) * 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
CZ302367B6 (cs) * 1998-09-30 2011-04-13 Eli Lilly And Company 2-Methylthienobenzodiazepinový prípravek
FR2802101B1 (fr) 1999-12-10 2003-02-28 Aventis Pharma Sa Association de cymemazine et d'un neuroleptique atypique
US7022698B2 (en) 1999-12-28 2006-04-04 U & I Pharmaceuticals, Ltd. Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
US6348458B1 (en) 1999-12-28 2002-02-19 U & I Pharmaceuticals Ltd. Polymorphic forms of olanzapine
EP1246827B1 (de) * 1999-12-28 2005-04-13 Cipla Limited Neue polymorphe formen von olanzapin
IL154688A0 (en) * 2000-08-31 2003-09-17 Reddys Lab Ltd Dr Hydrates of olanzapine and processes for the preparation thereof
WO2002019998A2 (en) * 2000-09-08 2002-03-14 Eli Lilly And Company A method of treating weight gain associated with atypical antipsychotic use
US6740753B2 (en) 2001-01-04 2004-05-25 Geneva Pharmaceuticals, Inc. Olanzapine crystal modification
EP1440074A1 (de) * 2001-10-29 2004-07-28 Dr. Reddy's Laboratories Ltd. Olanzapin dihydrat-ii, verfahren zu ihrer herstellung und ihre anwendung
AU2002367119A1 (en) * 2001-12-24 2003-07-15 Sun Pharmaceutical Industries Limited Crystalline form I of 2-methyl-4-(4-methyl-1-piperazinyl) 10H thieno [2,3-b][1,5]benzodiazepine
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US20050025791A1 (en) * 2002-06-21 2005-02-03 Julius Remenar Pharmaceutical compositions with improved dissolution
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004089313A2 (en) * 2003-04-01 2004-10-21 Transform Pharmaceuticals, Inc. Novel olanzapine forms and related methods of treatment
AU2003217676B2 (en) 2002-02-22 2009-06-11 Takeda Pharmaceutical Company Limited Active agent delivery systems and methods for protecting and administering active agents
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
PL196814B1 (pl) 2002-05-17 2008-02-29 Inst Farmaceutyczny Sposób wytwarzania odmiany polimorficznej I olanzapiny i jej solwaty
US7297789B2 (en) 2002-05-31 2007-11-20 Sandoz, Inc. Process of preparation of olanzapine form I
SI21270A (sl) 2002-07-15 2004-02-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Kristalne oblike olanzapina in postopki za njihovo pripravo
PL202856B1 (pl) * 2002-12-20 2009-07-31 Adamed Spo & Lstrok Ka Z Ogran Sposób otrzymywania farmaceutycznie czystej polimorficznej postaci I olanzapiny
US7323459B2 (en) 2002-12-24 2008-01-29 Teva Pharmaceutical Industries Ltd. Crystal forms, methods for their preparation and method for preparation of olanzapine
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ES2232332T3 (es) * 2003-03-12 2007-08-16 Teva Pharmaceutical Industries Ltd Composiciones farmaceuticas estables de desloratadina.
US20060135547A1 (en) * 2003-03-12 2006-06-22 Toth Zoltan G Stable pharmaceutical compositions of desloratadine and processes for preparation of polymorphic forms of desloratadine
GB0314149D0 (en) * 2003-06-18 2003-07-23 Generics Uk Ltd Novel amorphous forms
GB0326148D0 (en) 2003-11-10 2003-12-17 Lilly Co Eli Morpholine derivatives
CA2546200A1 (en) * 2003-11-18 2005-06-02 3M Innovative Properties Company Olanzapine containing transdermal drug delivery compositions
WO2005063771A1 (en) * 2003-12-22 2005-07-14 Teva Pharmaceutical Industries Ltd Methods of preparing olanzapine
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
ATE504588T1 (de) 2004-01-27 2011-04-15 Synthon Bv Stabile salze von olanzapin
ES2253091B1 (es) 2004-07-27 2007-02-01 Inke, S.A. Solvato mixto de olanzapina, procedimiento para su obtencion y procedimiento de obtencion de la forma i de olanzapina a partir del mismo.
US7829700B2 (en) 2004-09-06 2010-11-09 Shasun Chemicals And Drugs Limited Process for preparation of a pharmaceutically pure polymorphic form I of Olanzapine
ES2526092T3 (es) * 2004-11-16 2015-01-05 Alkermes Pharma Ireland Limited Formulaciones de olanzapina en nanopartículas inyectables
JP4940152B2 (ja) 2005-01-05 2012-05-30 イーライ リリー アンド カンパニー パモ酸オランザピン二水和物
CZ297214B6 (cs) * 2005-02-02 2006-10-11 Zentiva, A. S. Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
AR053562A1 (es) * 2005-03-21 2007-05-09 Reddys Lab Ltd Dr Proceso para la preparacion de la forma i cristalina de olanzapina
US20070021605A1 (en) * 2005-07-20 2007-01-25 Rolf Keltjens Process and composition for making olanzapine form i
EP1919923A1 (de) * 2005-08-17 2008-05-14 Synthon B.V. Verfahren zur herstellung von olanzapin form i
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
HUP0501046A2 (en) * 2005-11-11 2007-08-28 Egis Gyogyszergyar Nyilvanosan Process for the preparation of olanzapine
US8222184B2 (en) 2006-03-07 2012-07-17 Ncr Corporation UV and thermal guard
US8721202B2 (en) 2005-12-08 2014-05-13 Ncr Corporation Two-sided thermal print switch
US8367580B2 (en) 2006-03-07 2013-02-05 Ncr Corporation Dual-sided thermal security features
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
US7834176B2 (en) 2006-01-26 2010-11-16 Sandoz Ag Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
US7718649B1 (en) 2006-11-10 2010-05-18 Pisgah Labs, Inc. Physical states of a pharmaceutical drug substance
US8039461B1 (en) 2006-11-10 2011-10-18 Pisgah Laboratories, Inc. Physical states of a pharmaceutical drug substance
PL381564A1 (pl) 2007-01-22 2008-08-04 Koźluk Tomasz Nobilus Ent Sposób wytwarzania zasadniczo czystej odmiany polimorficznej I olanzapiny
CA2591644A1 (en) * 2007-06-14 2008-12-14 Apotex Pharmachem Inc. Novel processes to form-i of olanzapine
US9056488B2 (en) 2007-07-12 2015-06-16 Ncr Corporation Two-side thermal printer
US8883863B1 (en) 2008-04-03 2014-11-11 Pisgah Laboratories, Inc. Safety of psuedoephedrine drug products
CN101735239B (zh) * 2008-11-06 2011-08-31 齐鲁制药有限公司 一种无水奥氮平晶型ii的制备方法
EP2292624A1 (de) 2009-07-20 2011-03-09 LEK Pharmaceuticals d.d. Olanzapinreinigungsverfahren
EP3446565B1 (de) 2010-08-23 2023-11-01 Alkermes Pharma Ireland Limited Verfahren zur behandlung von durch antipsychotika induzierter gewichtszunahme
CN102093386B (zh) * 2011-01-05 2016-06-01 浙江华海药业股份有限公司 一种制备奥兰扎平晶型ⅱ的方法
WO2012153347A2 (en) 2011-05-04 2012-11-15 Zentiva K.S. Oral pharmaceutical composition of olanzapine form 1
CN104755928B (zh) 2012-08-21 2017-05-10 詹森药业有限公司 奥氮平的抗体及其用途
EP3581195B1 (de) * 2012-08-21 2025-10-01 Janssen Pharmaceutica NV Antikörper gegen olanzapinhaptene und verwendung davon
ES2926662T3 (es) 2012-08-21 2022-10-27 Janssen Pharmaceutica Nv Anticuerpos contra haptenos de risperidona y uso de los mismos
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103848847B (zh) * 2012-12-04 2018-02-06 广东东阳光药业有限公司 一种改进制备奥氮平及其晶型ii的方法
JP6008734B2 (ja) * 2012-12-20 2016-10-19 株式会社トクヤマ オランザピンｉｉ型結晶の製造方法
CN103145731B (zh) * 2013-02-26 2014-02-19 江苏豪森药业股份有限公司 奥氮平晶型及其制备方法和用途
KR20240130825A (ko) 2022-01-20 2024-08-29 테바 파마슈티컬스 인터내셔널 게엠베하 올란자핀, 이의 조성물 및 이의 사용 방법
LT4554562T (lt) 2023-01-10 2025-12-10 Medincell Sa Olanzapino kompozicijos ir panaudojimo būdai

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4305502A (en) 1977-07-20 1981-12-15 John Wyeth & Brother Limited Pharmaceutical dosage form packges
US4371516A (en) 1976-10-06 1983-02-01 John Wyeth & Brother Limited Articles for carrying chemicals
US4758598A (en) 1981-12-02 1988-07-19 John Wyeth & Brother Ltd. Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115568A (en) * 1974-11-26 1978-09-19 Lilly Industries Limited Thieno[3,2-b]-[1,5]benzodiazepines
US4237279A (en) * 1979-07-27 1980-12-02 Eli Lilly And Company Crystalline 3-hydroxycephalosporin solvates
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
CA2097016A1 (en) * 1992-05-29 1993-11-30 John Fairhurst Pharmaceutical compounds
US5439888A (en) * 1994-03-04 1995-08-08 Eli Lilly And Company Antithrombotic agents
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4371516A (en) 1976-10-06 1983-02-01 John Wyeth & Brother Limited Articles for carrying chemicals
US4305502A (en) 1977-07-20 1981-12-15 John Wyeth & Brother Limited Pharmaceutical dosage form packges
US4758598A (en) 1981-12-02 1988-07-19 John Wyeth & Brother Ltd. Solid shaped articles
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine

Also Published As

Publication number Publication date
LU90096B1 (fr) 1997-07-22
CA2214005C (en) 2001-07-03
NO314663B1 (no) 2003-04-28
SV1996000031A (es) 1998-03-27
SE9703205D0 (sv) 1997-09-05
ES2208220T3 (es) 2004-06-16
YU17796A (sh) 1999-03-04
IS1896B (is) 2003-10-20
NO974365L (no) 1997-09-22
DE69614426T2 (de) 2002-05-23
RO118872B1 (ro) 2003-12-30
AU706471B2 (en) 1999-06-17
HUP9802824A2 (hu) 1999-06-28
JPH11502535A (ja) 1999-03-02
FI973750A7 (fi) 1997-09-22
AU5427996A (en) 1996-10-16
ATE251627T1 (de) 2003-10-15
CA2214005A1 (en) 1996-10-03
SI0733635T1 (en) 2002-06-30
IL117610A (en) 2001-08-26
EP0733635A1 (de) 1996-09-25
ES2266719T3 (es) 2007-03-01
SE9703205L (sv) 1997-09-05
GB2313835A (en) 1997-12-10
ATE331719T1 (de) 2006-07-15
NZ306110A (en) 1998-09-24
TW442488B (en) 2001-06-23
AR002719A1 (es) 1998-04-29
KR19980703188A (ko) 1998-10-15
HU224989B1 (en) 2006-05-29
PA8353701A1 (es) 1998-09-18
PT1445259E (pt) 2006-10-31
DK1095941T3 (da) 2004-02-16
PT1095941E (pt) 2004-02-27
HUP9802824A3 (en) 2000-01-28
LV12018A (lv) 1998-04-20
CO4650278A1 (es) 1998-09-03
NO974365D0 (no) 1997-09-22
WO1996030375A1 (en) 1996-10-03
CN1179160A (zh) 1998-04-15
GB9719819D0 (en) 1997-11-19
LV12018B (en) 1998-09-20
EE03489B1 (et) 2001-08-15
MX9707183A (es) 1997-11-29
EP1095941A1 (de) 2001-05-02
SI1445259T1 (sl) 2006-10-31
HK1013988A1 (en) 1999-09-17
DE69630324T2 (de) 2004-07-29
SI1095941T1 (en) 2003-12-31
AT406771B (de) 2000-08-25
EG23659A (en) 2007-03-26
US5736541A (en) 1998-04-07
EP0733635B1 (de) 2001-08-16
EP1095941B1 (de) 2003-10-08
DE19681286T1 (de) 1998-04-02
UA44765C2 (uk) 2002-03-15
GB2313835B (en) 1998-09-16
CZ300097A3 (en) 1997-12-17
YU49478B (sh) 2006-05-25
PL322501A1 (en) 1998-02-02
DK108997A (da) 1997-11-12
BG101900A (en) 1999-03-31
BG62619B1 (bg) 2000-03-31
AP9701065A0 (en) 1997-10-31
AR010448A1 (es) 2000-06-28
IL117610A0 (en) 1996-07-23
PL183723B1 (pl) 2002-07-31
BR9607790A (pt) 1998-07-07
PE44897A1 (es) 1997-10-22
EE9700232A (et) 1998-04-15
ATE204280T1 (de) 2001-09-15
KR100399688B1 (ko) 2004-02-18
DK0733635T3 (da) 2001-10-08
FI973750A0 (fi) 1997-09-22
DE69636313T2 (de) 2007-05-31
OA10510A (en) 2002-04-24
DE69636313D1 (de) 2006-08-10
EA199700262A1 (ru) 1998-02-26
LT97148A (lt) 1998-01-26
IS4564A (is) 1997-09-22
SK284143B6 (sk) 2004-10-05
DK1445259T3 (da) 2006-10-16
ATA902196A (de) 2000-01-15
EA000149B1 (ru) 1998-10-29
TW513432B (en) 2002-12-11
TR199701017T1 (xx) 1998-01-21
PT733635E (pt) 2001-12-28
ZA962342B (en) 1997-09-22
SK121897A3 (en) 1998-03-04
CH690579A5 (de) 2000-10-31
EP1445259B1 (de) 2006-06-28
DE69630324D1 (de) 2003-11-13
AP828A (en) 2000-04-28
EP1445259A1 (de) 2004-08-11
SI9620040B (sl) 2002-02-28
DE69614426D1 (de) 2001-09-20
SI9620040A (sl) 1998-06-30
ES2159346T3 (es) 2001-10-01
CZ292688B6 (cs) 2003-11-12
MY114701A (en) 2002-12-31
FI973750L (fi) 1997-09-22
ZA962344B (en) 1997-09-22
CN1065536C (zh) 2001-05-09

Similar Documents

Publication Publication Date Title
LT4349B (lt) 2-metil-tieno-benzodiazepino kristalinės formos ir jų gavimo būdas
AU720366B2 (en) Olanzapine dihydrate D
JP2001501207A (ja) コーティングされた粒子製剤
ES2206614T3 (es) Uso de olanzapina o una sal farmaceuticamente aceptable para la preparacion de un medicamento para el tratamiento del autismo y del retraso mental.
HUT77907A (hu) 2-Metil-4-(4-metil-piperazino)-1OH-tieno[2,3-b][1,5] benzodiazepin alkalmazása kognitiv diszfunkció kezelésére gyógyszerkészítmények előállítására
CA2248753C (en) Use of olanzapine for treating excessive aggression
US6071902A (en) Method for treating excessive aggression
HK1013988B (en) Crystal forms of a thieno(2,3-b)(1,5) benzodiazepine derivative and process for their preparation
US20020177590A1 (en) Method for treating cognitive dysfunction
MXPA97007183A (en) A process and glass forms of 2-methyl-tieno-benzodiazep
KR19990087712A (ko) 불면증의 치료 방법

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20140322